Edition:
India

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

157.95USD
20 Apr 2018
Change (% chg)

$-0.77 (-0.49%)
Prev Close
$158.72
Open
$158.87
Day's High
$158.95
Day's Low
$156.74
Volume
76,801
Avg. Vol
138,006
52-wk High
$163.69
52-wk Low
$128.58

Chart for

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $8,797.71
Shares Outstanding(Mil.): 60.06
Dividend: --
Yield (%): --

Financials

  JAZZ.OQ Industry Sector
P/E (TTM): 22.31 30.95 32.74
EPS (TTM): 6.57 -- --
ROI: 10.38 14.84 14.38
ROE: 20.73 16.34 16.07

BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

* JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA

02 Mar 2018

BRIEF-Jazz Pharmaceuticals Q4 GAAP Earnings Per Share $3.79

* JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS

28 Feb 2018

BRIEF-Jazz Pharmaceuticals Enrolls First Patient In Clinical Trial of Defibrotide

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL EVALUATING DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE Source text for Eikon: Further company coverage:

23 Feb 2018

BRIEF-Jazz Pharma Submits New Drug Application For Solriamfetol (JZP-110)

* JAZZ PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY AND OBSTRUCTIVE SLEEP APNEA

21 Dec 2017

Pennsylvania man admits to trading on tips about drug company

Dec 15 A Pennsylvania man pleaded guilty on Friday to charges that he traded on confidential, inside information that a former Celator Pharmaceuticals Inc employee supplied him, including that the company now owned by Jazz Pharmaceuticals Plc was planning to be acquired.

16 Dec 2017

BRIEF-Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

* JAZZ PHARMACEUTICALS ANNOUNCES APPOINTMENT OF DANIEL SWISHER AS PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

05 Dec 2017

BRIEF-Jazz Pharmaceuticals posts Q3 EPS of $1.03

* Jazz pharmaceuticals announces third quarter 2017 financial results

08 Nov 2017

BRIEF-Jazz Pharma submits Vyxeo Marketing Authorization Application to European Medicines Agency

* Jazz Pharmaceuticals submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for treatment of certain types of high-risk acute myeloid leukemia Source text for Eikon: Further company coverage:

03 Nov 2017

Earnings vs. Estimates